Noting with concern that regulations, policies and practices, including those that limit legitimate trade of generic medicines, may seriously limit access to affordable HIV treatment and other pharmaceutical products in low- and middle-income countries, and recognizing that improvements can be made, inter alia, through national legislation, regulatory policy and supply chain management, and noting that reductions in barriers to affordable products could be explored in order to expand access to affordable and good-quality HIV prevention products, diagnostics, medicine and treatment commodities for HIV, including opportunistic infections and co-infections,